Novel therapies for pediatric acute myeloid leukemia: building future strategies through incorporation of treatment currently used in adults

DOI Web Site PubMed
  • MORITAKE Hiroshi
    Division of Pediatrics, Department of Developmental and Urological Reproductive Medicine, Faculty of Medicine, University of Miyazaki

Bibliographic Information

Other Title
  • 小児急性骨髄性白血病の新規治療
  • 小児急性骨髄性白血病の新規治療 : 成人治療からみた将来展望
  • ショウニ キュウセイ コツズイセイ ハッケツビョウ ノ シンキ チリョウ : セイジン チリョウ カラ ミタ ショウライ テンボウ
  • —成人治療からみた将来展望—

Search this article

Description

<p>In Japan, acute myeloid leukemia (AML) accounts for approximately 25% of all pediatric leukemias, with approximately 150 cases of newly diagnosed AML occurring annually. Approximately 10% of patients have primary induction failure and 30% of patients, who initially achieve remission in primary treatments, subsequently relapse. Novel treatment modalities need to be developed to further improve the prognosis of pediatric AML patients. AML is a heterogeneous genetic disease characterized by changes in the genome of hematopoietic progenitor cells. Recent studies that have made progress in research related to the pathogenesis of AML have suggested that genotype-specific treatment strategies are associated with increased efficacy. Potential new therapeutic alternatives for pediatric AML include: tyrosine kinase inhibitors, monoclonal or bispecific T-cell engager antibodies, chimeric antigen receptor T-cell therapy, and metabolic agents. This review highlights the current landscape of novel therapeutic approaches for childhood AML, including the results of both preclinical and clinical trials, as well as introducing the results of several preceding adult clinical studies, which could potentially be translated into pediatric AML patients.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 61 (6), 665-672, 2020

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top